Biotech

Aeglea BioTherapeutics (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced treatment of the first patients with pegzilarginase in two small cell lung cancer (SCLC) trials, the single-agent Phase 1 cohort expansion and the Phase 1/2 combination trial with KEYTRUDA®, an …

Aeglea BioTherapeutics (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced treatment of the first patients with pegzilarginase in two small cell lung cancer (SCLC) trials, the single-agent Phase 1 cohort expansion and the Phase 1/2 combination trial with KEYTRUDA®, an anti-PD-1 therapy marketed by Merck (known as MSD outside the United States and Canada).

As quoted in the press release:

The SCLC cohort expansion is one of three arms in a Phase 1 trial exploring pegzilarginase monotherapy in arginine dependent cancers. The combination therapy is part of the Company’s clinical collaboration to evaluate the use of pegzilarginase with KEYTRUDA, for the treatment of patients with SCLC. The multicenter Phase 1/2 study will evaluate overall response rate in patients with extensive disease SCLC who have relapsed or progressed after receiving platinum-based chemotherapy.

Click here to read the full press release.

Featured

MARKETS

Markets
TSX20595.89+4.91
TSXV846.29-0.92
DOW34168.09-129.64
S&P 5004349.93-6.52
NASD13542.12+2.82
ASX6961.60-177.90

COMMODITIES

Commodities
Gold1818.70-3.17
Silver23.55-0.03
Copper4.46-0.05
Palladium2330.00+10.99
Platinum1037.28+2.57
Oil87.28-0.07
Heating Oil2.69-0.01
Natural Gas4.25-0.02

DOWNLOAD FREE REPORTS

×